Replies to post #19185 on Seelos Therapeutics Inc (SEELQ)

[Dimitrios George]

SB,

I am not mad at you. I just think it is "too funny" the lengths that you are going to in order to correct up your previous thesis on Femprox. However, your need to hammer that point is tiring. The rest of us know what the score is on Femprox. And that score does not include your misinterpretation of what Pascoe told Eman. Not getting a deal does not mean that there was no solid interest...if you can follow triple negatives.

I do expect you to "redeploy" your resources at $2.40 or there about. I figured you would do so at $2.30.

I will stand by my metaphors, even if they aren't gender neutral, although gender had nothing to do with my point.

[Shazam619]

Femprox is probably "dead" for 2014 but could come back to life in 2015. We don't know how much interest there is in Femprox but what we do know is that there isn't the kind of interest Pascoe wants until there's some clarity from the FDA on FSAID.

I think dead is being interpreted as never coming back and that's not the case with Femprox. If we the FDA rejected it and Pascoe said they were going to stop pursuing it then it would be dead.

If you were running this company all of the management would have been hired and fired within a month. That's not a good way to acquire or retain talent. Pascoe's doing a good job but has told us too much. Most companies don't release this much information. Then they don't have to back track when there's a problem.

In my opinion Femprox should never have taken a front seat over Vitaros. The product that generates the most money this year should be our focus and that's going to be Vitaros for a couple years. Then RayVa, and finally Femprox. Hopefully there will be some good surprises added on to that in 2015.

With all these launches pending, I find myself wondering if we'll have some news every Monday. :)